Display options
Cite
Kroonen JS, Kruisselbrink AB, Briaire-de Bruijn IH, et al. SUMOylation Is Associated with Aggressive Behavior in Chondrosarcoma of Bone. Cancers (Basel). 2021;13(15)doi: 10.3390/cancers13153823.
Kroonen, J. S., Kruisselbrink, A. B., Briaire-de Bruijn, I. H., Olaofe, O. O., Bovée, J. V. M. G., & Vertegaal, A. C. O. (2021). SUMOylation Is Associated with Aggressive Behavior in Chondrosarcoma of Bone. Cancers, 13(15), . https://doi.org/10.3390/cancers13153823
Kroonen, Jessie S, et al. "SUMOylation Is Associated with Aggressive Behavior in Chondrosarcoma of Bone." Cancers vol. 13,15 (2021). doi: https://doi.org/10.3390/cancers13153823
Kroonen JS, Kruisselbrink AB, Briaire-de Bruijn IH, Olaofe OO, Bovée JVMG, Vertegaal ACO. SUMOylation Is Associated with Aggressive Behavior in Chondrosarcoma of Bone. Cancers (Basel). 2021 Jul 29;13(15). doi: 10.3390/cancers13153823. PMID: 34359724; PMCID: PMC8345166.
Copy Download .nbib Format: NLM
Share it on

Cancers (Basel). 2021 Jul 29;13(15). doi: 10.3390/cancers13153823.

SUMOylation Is Associated with Aggressive Behavior in Chondrosarcoma of Bone.

Cancers

Jessie S Kroonen, Alwine B Kruisselbrink, Inge H Briaire-de Bruijn, Olaejirinde O Olaofe, Judith V M G Bovée, Alfred C O Vertegaal

Affiliations

  1. Department of Cell and Chemical Biology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
  2. Department of Pathology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.

PMID: 34359724 PMCID: PMC8345166 DOI: 10.3390/cancers13153823

Abstract

Multiple components of the SUMOylation machinery are deregulated in various cancers and could represent potential therapeutic targets. Understanding the role of SUMOylation in tumor progression and aggressiveness would increase our insight in the role of SUMO in cancer and clarify its potential as a therapeutic target. Here we investigate SUMO in relation to conventional chondrosarcomas, which are malignant cartilage forming tumors of the bone. Aggressiveness of chondrosarcoma increases with increasing histological grade, and a multistep progression model is assumed. High-grade chondrosarcomas have acquired an increased number of genetic alterations. Using immunohistochemistry on tissue microarrays (TMA) containing 137 chondrosarcomas, we showed that higher expression of SUMO1 and SUMO2/3 correlates with increased histological grade. In addition, high SUMO2/3 expression was associated with decreased overall survival chances (

Keywords: ML792; SUMO; cell cycle; chondrosarcoma; survival

References

  1. Cell Chem Biol. 2019 Feb 21;26(2):278-288.e6 - PubMed
  2. Gut. 2020 Aug;69(8):1472-1482 - PubMed
  3. Dev Cell. 2005 Dec;9(6):769-79 - PubMed
  4. Mol Cell. 2002 Jun;9(6):1169-82 - PubMed
  5. Oncotarget. 2015 May 20;6(14):12505-19 - PubMed
  6. J Pathol. 2015 Jul;236(3):348-59 - PubMed
  7. Oncogene. 2004 Mar 15;23(11):1998-2008 - PubMed
  8. Nat Chem Biol. 2017 Oct 18;13(11):1141-1142 - PubMed
  9. Genes Chromosomes Cancer. 2012 Oct;51(10):899-909 - PubMed
  10. Cell. 2008 Apr 4;133(1):103-15 - PubMed
  11. EMBO Rep. 2014 Aug;15(8):878-85 - PubMed
  12. Mol Cell. 2014 Mar 20;53(6):1053-66 - PubMed
  13. Nat Rev Cancer. 2017 Mar;17(3):184-197 - PubMed
  14. Lab Invest. 2003 Jun;83(6):877-87 - PubMed
  15. Sci Rep. 2016 Nov 30;6:37775 - PubMed
  16. Cancer Res. 2008 Apr 1;68(7):2409-18 - PubMed
  17. Nat Rev Cancer. 2010 Jul;10(7):481-8 - PubMed
  18. Mol Cell Biol. 2006 Jun;26(12):4489-98 - PubMed
  19. Oncogene. 2014 Aug 21;33(34):4316-29 - PubMed
  20. Br J Cancer. 2013 Sep 3;109(5):1214-22 - PubMed
  21. Cell Rep. 2021 Mar 30;34(13):108929 - PubMed
  22. Genes Dev. 2013 Apr 15;27(8):836-52 - PubMed
  23. J Surg Oncol. 2017 Aug;116(2):252-257 - PubMed
  24. Eur J Cancer. 2007 Sep;43(14):2060-5 - PubMed
  25. Nat Methods. 2016 Jun;13(6):521-7 - PubMed
  26. PLoS One. 2015 Apr 10;10(4):e0123882 - PubMed
  27. Sci Rep. 2021 Mar 15;11(1):6047 - PubMed
  28. Clin Orthop Relat Res. 2000 Jul;(376):291-303 - PubMed
  29. Nat Commun. 2018 Mar 16;9(1):1119 - PubMed
  30. Nat Commun. 2019 Oct 11;10(1):4622 - PubMed
  31. J BUON. 2016 Jan-Feb;21(1):244-51 - PubMed
  32. Nat Chem Biol. 2017 Nov;13(11):1164-1171 - PubMed
  33. J Cell Biol. 2003 Nov 24;163(4):729-41 - PubMed
  34. Clin Cancer Res. 2016 Jan 1;22(1):34-43 - PubMed
  35. J Cell Biol. 2003 Nov 10;163(3):477-87 - PubMed
  36. Annu Rev Biochem. 2013;82:357-85 - PubMed
  37. Curr Top Microbiol Immunol. 2007;313:49-71 - PubMed
  38. Nat Commun. 2019 Sep 4;10(1):3987 - PubMed
  39. Am J Pathol. 2013 Apr;182(4):1347-56 - PubMed
  40. Surg Oncol. 2018 Sep;27(3):402-408 - PubMed
  41. Nature. 2009 Dec 10;462(7274):739-44 - PubMed
  42. J Med Chem. 2021 Mar 11;64(5):2501-2520 - PubMed
  43. J Bone Oncol. 2019 Jan 29;15:100222 - PubMed
  44. J Clin Oncol. 2005 Dec 20;23(36):9369-76 - PubMed
  45. Br J Cancer. 2018 Apr;118(8):1074-1083 - PubMed
  46. Virchows Arch. 2007 Sep;451(3):691-9 - PubMed
  47. Nat Genet. 2011 Nov 06;43(12):1256-61 - PubMed
  48. Trends Biochem Sci. 2018 Apr;43(4):251-268 - PubMed
  49. Cells. 2020 Apr 14;9(4): - PubMed
  50. Mol Cell. 2013 Mar 7;49(5):795-807 - PubMed
  51. Nat Commun. 2014 Dec 05;5:5485 - PubMed
  52. J Biol Chem. 2011 Apr 22;286(16):14516-30 - PubMed
  53. Nature. 1999 Mar 18;398(6724):246-51 - PubMed
  54. Nat Rev Mol Cell Biol. 2016 Sep;17(9):581-95 - PubMed
  55. Cancers (Basel). 2019 Dec 02;11(12): - PubMed
  56. J Biol Chem. 2004 Aug 6;279(32):33791-8 - PubMed
  57. Nat Med. 2018 Feb;24(2):186-193 - PubMed
  58. Elife. 2018 Mar 08;7: - PubMed
  59. Nat Commun. 2016 Jul 28;7:12326 - PubMed
  60. Trends Biochem Sci. 2015 Dec;40(12):779-793 - PubMed
  61. Trends Biochem Sci. 2003 Nov;28(11):612-8 - PubMed
  62. Eur Spine J. 2018 Dec;27(12):3043-3058 - PubMed
  63. Cancer. 1974 Apr;33(4):1027-33 - PubMed
  64. BMC Cancer. 2012 Aug 28;12:375 - PubMed
  65. Chem Rev. 2018 Feb 14;118(3):889-918 - PubMed
  66. Trends Cancer. 2021 Jun;7(6):496-510 - PubMed
  67. Blood. 2014 Sep 25;124(13):2081-90 - PubMed
  68. Cell Cycle. 2009 Jul 15;8(14):2211-8 - PubMed
  69. J Cell Biol. 2010 Mar 8;188(5):681-92 - PubMed
  70. Pathol Oncol Res. 2012 Oct;18(4):793-802 - PubMed
  71. J Cell Biol. 2016 Jun 20;213(6):665-78 - PubMed
  72. J Pathol. 2011 Jul;224(3):334-43 - PubMed

Publication Types

Grant support